Status:
RECRUITING
GWAS to Identify Predictive Genetic Factors for the Success of Dietary Intervention in the Treatment of IBS Symptoms
Lead Sponsor:
Attikon Hospital
Conditions:
Irritable Bowel Syndrome (IBS)
Genome-wide Association Study
Eligibility:
All Genders
18-65 years
Brief Summary
This is a GWAS that aims to identify possible single nucleotide polymorphisms (SNPs) that are associated with the response in a combined dietary pattern low in fermentable oligosaccharides, disacchari...
Detailed Description
Irritable bowel syndrome (IBS) is a very common chronic gastrointestinal disorder. Several factors seem to contribute to its development, such as psychological stress, intestinal dysbiosis, infections...
Eligibility Criteria
Inclusion
- Fulfillment of the Rome IV criteria for IBS
- Provision of written informed consent.
- Commitment of availability throughout the study period.
- IBS-SSS \> 175
Exclusion
- Any concomitant disease requiring specialized nutrition (e.g. renal failure, diabetes, celiac disease, cerebrovascular disease of the central nervous system, major surgical cavity).
- Pregnancy.
- Breastfeeding.
Key Trial Info
Start Date :
September 15 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 15 2027
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06912828
Start Date
September 15 2024
End Date
February 15 2027
Last Update
April 6 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Attikon General University Hospital of Athens
Athens, Greece, 12462